Canada's Institute for Advanced Medical Isotopes research and development facility will use an advanced, high-capacity TR-24 cyclotron for technetium-99m production and radiopharmaceutical production laboratories to provide next-generation cancer treatments, as well as shore up local supply of critical medical radioisotopes, in an effort to bolster the country's hold in the nuclear medicine sector. Completion of the facility is expected by March 2020, and it should be fully online by the end of that year.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.